STAT

AUGUST 16, 2024

  The Centers for Medicare & Medicaid Services released the Maximum Fair Prices (MFPs) for the first 10 drugs subject to negotiation under the Inflation Reduction Act. This is an important moment in prescription drug pricing policy. billion ) in 2026.

Drug Pricing 269

Drug Pricing Diabetes 269

STAT

AUGUST 22, 2023

German drugmaker Boehringer Ingelheim is the latest pharmaceutical company to sue the federal government over a law that would allow Medicare to negotiate certain drug prices, Reuters reports. Continue to STAT+ to read the full story…

Vaccines 246

Vaccines Drug Pricing Diabetes Pharmaceutical Companies 246

Pharmaceutical Commerce

AUGUST 16, 2024

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

Drug Pricing 98

Drug Pricing Diabetes 98

STAT

SEPTEMBER 18, 2024

  A Novo Nordisk executive believes that Ozempic, the blockbuster diabetes shot made by the company, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the Medicare program, Bloomberg News writes. The Inflation Reduction Act, which allows the U.S.

Hospitals 264

Hospitals Drug Pricing Diabetes 264

Putting Patients First Blog

JULY 2, 2024

General Comments The NHC appreciates CMS’ commitment to actively engaging with stakeholders, including patients, consumer advocates, and health experts, in implementing the Medicare Drug Price Negotiation Program (DPNP). Active Moiety and Single Source Qualifying Drugs (Section 30.1)

Drug Pricing 52

Drug Pricing Insurance Coverage and Processing Labelling HIPAA 52

Putting Patients First Blog

JANUARY 27, 2025

The NHC recognizes that Medicare already covers AOMs for patients who are overweight and have comorbid conditions such as diabetes or cardiovascular disease. Issue Brief: Improving Prescription Drug Price and Cost Transparency. link] www.ama-assn.org/system/files/issue- brief-improving-drug-price-cost-transparency.pdf.

Insurance Coverage and Processing 40

Insurance Coverage and Processing Biosimilars Communication Department of Veterans Affairs 40

Safe Biologics

APRIL 10, 2023

CMS Releases Guidance Memo on Medicare Drug Price Negotiation; Allows Only 30 Days to Comment On March 15, 2023, the Centers for Medicare and Medicaid (CMS) released an initial Guidance Memo regarding implementation of its Medicare Drug Price Negotiation Program, authorized by the Inflation Reduction Act (IRA) signed into law August 16, 2022.

Biosimilars 130

Biosimilars Drug Pricing Diabetes Labelling 130